Clinical Trials Logo

Filter by:
NCT ID: NCT04351958 Not yet recruiting - Harm Reduction Clinical Trials

An Augmented Reality Videogame for Alcohol Use Prevention and Harm Reduction in Teens

Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this research study is to develop the AR-based alcohol use prevention and harm reduction intervention, "No Time Wasted", with the further aim of conducting a pre-post pilot study to assess whether the game reduce risk behaviors associated with alcohol use, whilst also increasing knowledge about some of the following topics: BAC, standard drink sizes, signs of alcohol poisoning. The intervention will also seek to encourage bystander intervention to assist fictional characters in need of help due to overdrinking.

NCT ID: NCT04350996 Not yet recruiting - Alcohol Drinking Clinical Trials

Continuous Alcohol Monitoring for Pancreatitis

CAMP
Start date: June 2020
Phase:
Study type: Observational

The purpose the research is to demonstrate the feasibility of using a transdermal alcohol sensing device (BACtrack Skyn), and to correlate biological and self-reported alcohol measures with the transdermal alcohol measures in patients with a history of pancreatitis. The results from this study will inform tailored, self-directed interventions for reducing alcohol consumption in persons with pancreatitis.

NCT ID: NCT04345705 Not yet recruiting - Mesothelioma Clinical Trials

Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

Start date: May 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to offer a novel cancer vaccine called poly-ICLC (Hiltonol®) for subjects with malignant pleural mesothelioma by directly injecting the vaccine into the tumor. This trial will enroll a maximum of 18 patients with biopsy proven malignant pleural mesothelioma who are surgically resectable. Subjects will undergo core biopsies of their mesothelioma followed by direct injection of Poly ICLC, a TLR3 agonist which has been shown to have biological and immunological effects. Within two to three weeks following the injection, the patients will undergo a pleurectomy/decortication or EPP, as is standard of care. Tissue resected at that time will be compared to tissue obtained at biopsy prior to the injection of the immunological agent.

NCT ID: NCT04343677 Not yet recruiting - COVID-19 Clinical Trials

Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study

Start date: April 2020
Phase: Phase 2
Study type: Interventional

There is significant interest throughout the United States in performing a well-designed study to evaluate whether there is value in using Hydroxychloroquine or Chloroquine as a pre-exposure prophylaxis or post-exposure prophylaxis regimen for COVID-19 patients and at risk personnel. We have designed a prospective double blinded randomized controlled clinical trial to answer just this question. The study will consist of 4 arms: 1. A placebo control arm of 450 patients 2. A low dose prophylaxis arm of 450 patients treated with 200mg Hydroxychloroquine daily 3. A high dose prophylaxis arm of 450 patients treated with 400mg Hydroxychloroquine daily 4. A post-exposure arm of 100 patients treated with 400mg Hydroxychloroquine daily for 7 days.

NCT ID: NCT04337216 Not yet recruiting - COVID-19 Clinical Trials

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation

Start date: May 2020
Phase: Phase 2
Study type: Interventional

The primary endpoint of this study is to assess the effects of a single IV dose of mavrilimumab on the acute inflammatory response in patients with severe COVID-19 pneumonia

NCT ID: NCT04333290 Not yet recruiting - Healthy Clinical Trials

Study Evaluating the Safety of Myeliviz Myelin-Targeting PET Agent

Start date: March 2025
Phase: Early Phase 1
Study type: Interventional

This study evaluates the safety of [11C]MeDAS, a PET radiotracer.

NCT ID: NCT04329221 Not yet recruiting - Skin Cancer Clinical Trials

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Start date: January 1, 2026
Phase: Phase 2
Study type: Interventional

This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-fluorouracil cream as an immunotherapy for actinic keratosis in Organ Transplant Recipients (OTRs) before transplantation and determine whether it can prevent cutaneous squamous cell carcinoma (SCC) in OTRs post-transplant.

NCT ID: NCT04322734 Not yet recruiting - Epilepsy Clinical Trials

Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders

Start date: July 1, 2024
Phase:
Study type: Observational

Researchers in the Neurodevelopmental Division at Phoenix Children's Hospital are conducting a study about mitochondrial function in children with autism spectrum disorder (ASD). The study involves up to 5 visits to Phoenix Children's Hospital with fasting blood draws, behavioral assessments, and/or questionnaires. Other samples may be collected when appropriate. This study is currently recruiting. There is no cost for visits or study-related exams.

NCT ID: NCT04318249 Not yet recruiting - Insomnia Clinical Trials

Behavioral Relaxation Approaches for Insomnia in Lung Cancer Patients

LC_ART
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

This is a randomized, 30-day research study that is exploring the effects of two simplified mindfulness interventions in lung cancer patients aimed to improve their sleep quality and anxiety regarding sleep. The investigators will be enrolling a total of 20 patients who have insomnia symptoms. Patients will use a behavioral intervention to help with their sleep.

NCT ID: NCT04315675 Not yet recruiting - HIV/AIDS Clinical Trials

Improve Functional Health Status in Minority Women With HIV

Start date: April 1, 2020
Phase: N/A
Study type: Interventional

HIV is no longer a death sentence, and with adherence to Rapid High Activity Antiretroviral (HAART) protocol women with HIV can achieve a normal life expectancy. In New Jersey there are 11,724 (32.9%) women living with HIV with Essex county in the lead, and they come they come from lowest social strata and educational level and are often single mothers. The purpose of this study is test three study interventions: a cognitive health promotion intervention, a guided imagery intervention and combination of both interventions. The Significance of the study is to improve the functional health and protocol adherence, to better enable women with HIV to achieve a normal life expectancy. The Methodology is an intervention study that uses a classic four group pretest post-test experimental design with random assignment, and the subjects for the study will be 80 women living with HIV. The interventions will be delivered within a three-week time frame followed by post testing at the end of the third week in Newark,New Jersey. The results of this study will be used as preliminary data to support a grant proposal to be submitted to the National Institutes of Health. The Results of this study are important as they will support improved health function and adherence to treatment protocols for marginalized poor women with HIV to achieve outcomes on par with men.